Ryvu Therapeutics Statistics

Total Valuation

Ryvu Therapeutics has a market cap or net worth of PLN 601.12 million. The enterprise value is 434.52 million.

Market Cap	601.12M
Enterprise Value	434.52M

Important Dates

The next estimated earnings date is Friday, March 14, 2025.

Earnings Date	Mar 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Ryvu Therapeutics has 23.12 million shares outstanding. The number of shares has increased by 6.52% in one year.

Current Share Class	n/a
Shares Outstanding	23.12M
Shares Change (YoY)	+6.52%
Shares Change (QoQ)	+11.15%
Owned by Insiders (%)	23.80%
Owned by Institutions (%)	52.82%
Float	15.70M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.59
PB Ratio	3.38
P/TBV Ratio	3.54
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.17
EV / Sales	4.77
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-3.30

Financial Position

The company has a current ratio of 3.03, with a Debt / Equity ratio of 0.46.

Current Ratio	3.03
Quick Ratio	2.78
Debt / Equity	0.46
Debt / EBITDA	n/a
Debt / FCF	-0.61
Interest Coverage	-49.17

Financial Efficiency

Return on equity (ROE) is -44.88% and return on invested capital (ROIC) is -23.58%.

Return on Equity (ROE)	-44.88%
Return on Assets (ROA)	-15.56%
Return on Invested Capital (ROIC)	-23.58%
Return on Capital Employed (ROCE)	-34.33%
Revenue Per Employee	337,700
Profits Per Employee	-385,693
Employee Count	270
Asset Turnover	0.22
Inventory Turnover	7.90

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -49.91% in the last 52 weeks. The beta is 0.65, so Ryvu Therapeutics's price volatility has been lower than the market average.

Beta (5Y)	0.65
52-Week Price Change	-49.91%
50-Day Moving Average	39.32
200-Day Moving Average	48.45
Relative Strength Index (RSI)	21.48
Average Volume (20 Days)	16,302

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Ryvu Therapeutics had revenue of PLN 91.18 million and -104.14 million in losses. Loss per share was -4.52.

Revenue	91.18M
Gross Profit	72.50M
Operating Income	-104.93M
Pretax Income	-104.00M
Net Income	-104.14M
EBITDA	-95.25M
EBIT	-104.93M
Loss Per Share	-4.52

Full Income Statement

Balance Sheet

The company has 247.55 million in cash and 80.94 million in debt, giving a net cash position of 166.61 million or 7.21 per share.

Cash & Cash Equivalents	247.55M
Total Debt	80.94M
Net Cash	166.61M
Net Cash Per Share	7.21
Equity (Book Value)	177.75M
Book Value Per Share	7.69
Working Capital	198.24M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -121.03 million and capital expenditures -10.65 million, giving a free cash flow of -131.68 million.

Operating Cash Flow	-121.03M
Capital Expenditures	-10.65M
Free Cash Flow	-131.68M
FCF Per Share	-5.70

Full Cash Flow Statement

Margins

Gross margin is 79.51%, with operating and profit margins of -115.08% and -114.21%.

Gross Margin	79.51%
Operating Margin	-115.08%
Pretax Margin	-114.06%
Profit Margin	-114.21%
EBITDA Margin	-104.46%
EBIT Margin	-115.08%
FCF Margin	n/a

Dividends & Yields

Ryvu Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.52%
Shareholder Yield	-6.52%
Earnings Yield	-17.32%
FCF Yield	-21.91%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Ryvu Therapeutics has an Altman Z-Score of 3.13.

Altman Z-Score	3.13
Piotroski F-Score	n/a